Health & Biotech
Singular Health officially enters the Mediverse
Health & Biotech
EZZ launches new products to support digestive health
Health & Biotech
ASX Health Stocks: Arovella and Imugene break away from the pack on major announcements
Health & Biotech
Dr Boreham’s Crucible: Visoneering’s taking the longview on short-sightedness – and it’s starting to pay off
Health & Biotech
ScoPo’s Powerplays: Neuren breakthrough, M&A deals, and why EBOS ticks ESG boxes
Health & Biotech
ASX Health Stocks: Aussie biotechs Argenica and Antisense take major steps in the US
Health & Biotech
Wellnex Life signs JV with Australian Dairy to launch A2 infant formula across shelves
Health & Biotech
Cannabis play Epsilon boosted by $2.9m fresh capital as it targets profit in 2022
Health & Biotech
HealthKick Podcast: Life sciences expert on local medical innovations, tech leaders and sector opportunities
Health & Biotech
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
Health & Biotech
Neuren’s stock price doubles on groundbreaking drug trial, CEO says it’s ‘just getting started’
Health & Biotech
Weed Week: An Aussie company mistakenly named in Taliban weed deal and new research could shake up cannabis driving laws
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.